118 related articles for article (PubMed ID: 34475047)
1. Preclinical Activity of Plitidepsin Against Clear Cell Carcinoma of the Ovary.
Miyake R; Yamanaka S; Matsubara S; Mabuchi S
Anticancer Res; 2021 Sep; 41(9):4277-4285. PubMed ID: 34475047
[TBL] [Abstract][Full Text] [Related]
2. Preclinical Efficacy for AKT Targeting in Clear Cell Carcinoma of the Ovary.
Sasano T; Mabuchi S; Kuroda H; Kawano M; Matsumoto Y; Takahashi R; Hisamatsu T; Sawada K; Hashimoto K; Isobe A; Testa JR; Kimura T
Mol Cancer Res; 2015 Apr; 13(4):795-806. PubMed ID: 25519148
[TBL] [Abstract][Full Text] [Related]
3. Translation Elongation Factor eEF1A2 is a Novel Anticancer Target for the Marine Natural Product Plitidepsin.
Losada A; Muñoz-Alonso MJ; García C; Sánchez-Murcia PA; Martínez-Leal JF; Domínguez JM; Lillo MP; Gago F; Galmarini CM
Sci Rep; 2016 Oct; 6():35100. PubMed ID: 27713531
[TBL] [Abstract][Full Text] [Related]
4. Preclinical Investigations of PM01183 (Lurbinectedin) as a Single Agent or in Combination with Other Anticancer Agents for Clear Cell Carcinoma of the Ovary.
Takahashi R; Mabuchi S; Kawano M; Sasano T; Matsumoto Y; Kuroda H; Kozasa K; Hashimoto K; Sawada K; Kimura T
PLoS One; 2016; 11(3):e0151050. PubMed ID: 26986199
[TBL] [Abstract][Full Text] [Related]
5. The activity of trabectedin as a single agent or in combination with everolimus for clear cell carcinoma of the ovary.
Mabuchi S; Hisamatsu T; Kawase C; Hayashi M; Sawada K; Mimura K; Takahashi K; Takahashi T; Kurachi H; Kimura T
Clin Cancer Res; 2011 Jul; 17(13):4462-73. PubMed ID: 21622721
[TBL] [Abstract][Full Text] [Related]
6. Combination treatment with trabectedin and irinotecan or topotecan has synergistic effects against ovarian clear cell carcinoma cells.
Kawano M; Mabuchi S; Kishimoto T; Hisamatsu T; Matsumoto Y; Sasano T; Takahashi R; Sawada K; Takahashi K; Takahashi T; Hamasaki T; Kimura T
Int J Gynecol Cancer; 2014 Jun; 24(5):829-37. PubMed ID: 24844217
[TBL] [Abstract][Full Text] [Related]
7. PDK2 leads to cisplatin resistance through suppression of mitochondrial function in ovarian clear cell carcinoma.
Kitamura S; Yamaguchi K; Murakami R; Furutake Y; Higasa K; Abiko K; Hamanishi J; Baba T; Matsumura N; Mandai M
Cancer Sci; 2021 Nov; 112(11):4627-4640. PubMed ID: 34464482
[TBL] [Abstract][Full Text] [Related]
8. Galectin-3 may contribute to Cisplatin resistance in clear cell carcinoma of the ovary.
Oishi T; Itamochi H; Kigawa J; Kanamori Y; Shimada M; Takahashi M; Shimogai R; Kawaguchi W; Sato S; Terakawa N
Int J Gynecol Cancer; 2007; 17(5):1040-6. PubMed ID: 17433067
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of autophagy protein LC3A as a therapeutic target in ovarian clear cell carcinomas.
Miyamoto M; Takano M; Aoyama T; Soyama H; Yoshikawa T; Tsuda H; Furuya K
J Gynecol Oncol; 2017 May; 28(3):e33. PubMed ID: 28382796
[TBL] [Abstract][Full Text] [Related]
10. Expression of eEF1A2 is associated with clear cell histology in ovarian carcinomas: overexpression of the gene is not dependent on modifications at the EEF1A2 locus.
Tomlinson VA; Newbery HJ; Bergmann JH; Boyd J; Scott D; Wray NR; Sellar GC; Gabra H; Graham A; Williams AR; Abbott CM
Br J Cancer; 2007 May; 96(10):1613-20. PubMed ID: 17437010
[TBL] [Abstract][Full Text] [Related]
11. Characterization of ovarian clear cell carcinoma using target drug-based molecular biomarkers: implications for personalized cancer therapy.
Li M; Li H; Liu F; Bi R; Tu X; Chen L; Ye S; Cheng X
J Ovarian Res; 2017 Feb; 10(1):9. PubMed ID: 28187748
[TBL] [Abstract][Full Text] [Related]
12. X-chromosome-linked inhibitor of apoptosis as a key factor for chemoresistance in clear cell carcinoma of the ovary.
Miyamoto M; Takano M; Iwaya K; Shinomiya N; Kato M; Aoyama T; Sasaki N; Goto T; Suzuki A; Hitrata J; Furuya K
Br J Cancer; 2014 Jun; 110(12):2881-6. PubMed ID: 24853184
[TBL] [Abstract][Full Text] [Related]
13. Antitumor effects of interleukin-6 (IL-6)/interleukin-6 receptor (IL-6R) signaling pathway inhibition in clear cell carcinoma of the ovary.
Yanaihara N; Hirata Y; Yamaguchi N; Noguchi Y; Saito M; Nagata C; Takakura S; Yamada K; Okamoto A
Mol Carcinog; 2016 May; 55(5):832-41. PubMed ID: 25856562
[TBL] [Abstract][Full Text] [Related]
14. The Anti-tumor Effect of Cabozantinib on Ovarian Clear Cell Carcinoma
Nakatani M; Watari H; Mitamura T; Wang L; Hatanaka Y; Hatanaka KC; Honda K; Nomura T; Nishihara H; Tanaka S; Sakuragi N
Anticancer Res; 2017 Nov; 37(11):6125-6132. PubMed ID: 29061793
[TBL] [Abstract][Full Text] [Related]
15. Impact of iASPP on chemoresistance through PLK1 and autophagy in ovarian clear cell carcinoma.
Chan KK; Wong OG; Wong ES; Chan KK; Ip PP; Tse KY; Cheung AN
Int J Cancer; 2018 Sep; 143(6):1456-1469. PubMed ID: 29663364
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of cisplatin resistance in clear cell carcinoma of the ovary.
Itamochi H; Kigawa J; Akeshima R; Sato S; Kamazawa S; Takahashi M; Kanamori Y; Suzuki M; Ohwada M; Terakawa N
Oncology; 2002; 62(4):349-53. PubMed ID: 12138243
[TBL] [Abstract][Full Text] [Related]
17. A novel retinoid, 4-[3,5-bis (trimethylsilyl) benzamido] benzoic acid (TAC-101), induces apoptosis of human ovarian carcinoma cells and shows potential as a new antitumor agent for clear cell adenocarcinoma.
Suzuki N; Aoki D; Oie S; Horiuchi M; Hasegawa Y; Ezawa S; Suzuki A; Susumu N; Hosoi F; Kitazato K; Nozawa S
Gynecol Oncol; 2004 Sep; 94(3):643-9. PubMed ID: 15350353
[TBL] [Abstract][Full Text] [Related]
18. The prognostic significance of elongation factor eEF1A2 in ovarian cancer.
Pinke DE; Kalloger SE; Francetic T; Huntsman DG; Lee JM
Gynecol Oncol; 2008 Mar; 108(3):561-8. PubMed ID: 18164751
[TBL] [Abstract][Full Text] [Related]
19. Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma.
Tsuchiya A; Sakamoto M; Yasuda J; Chuma M; Ohta T; Ohki M; Yasugi T; Taketani Y; Hirohashi S
Am J Pathol; 2003 Dec; 163(6):2503-12. PubMed ID: 14633622
[TBL] [Abstract][Full Text] [Related]
20. Vascular endothelial growth factor is a promising therapeutic target for the treatment of clear cell carcinoma of the ovary.
Mabuchi S; Kawase C; Altomare DA; Morishige K; Hayashi M; Sawada K; Ito K; Terai Y; Nishio Y; Klein-Szanto AJ; Burger RA; Ohmichi M; Testa JR; Kimura T
Mol Cancer Ther; 2010 Aug; 9(8):2411-22. PubMed ID: 20663925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]